Skip to main content

Table 3 Prediction of pCR and residual tumor size in the MRI group and in the US group

From: Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials

Group   pCR, N CR, N TN, N FP, N TP, N FN, N Specificity (CL) Sensitivity (CL) NPV (CL) PPV (CL)
Overall MRI (N = 244) 89 84 61 28 132 23 0.69 (0.58–0.78) 0.85 (0.79–0.90) 0.73 (0.62–0.82) 0.83 (0.76–0.88)
US (N = 578) 218 149 101 117 312 48 0.46 (0.40–0.53) 0.87 (0.83–0.90) 0.68 (0.60–0.75) 0.73 (0.68–0.77)
HR+/HER2+ MRI (N = 103) 34 25 19 15 63 6 0.56 (0.38–0.73) 0.91 (0.82–0.97) 0.76 (0.55–0.91) 0.81 (0.70–0.89)
US (N = 252) 83 62 39 44 146 23 0.47 (0.36–0.58) 0.86 (0.80–0.91) 0.63 (0.50–0.75) 0.77 (0.70–0.83)
HR−/HER2− MRI (N = 91) 31 38 22 9 44 15 0.71 (0.52–0.86) 0.73 (0.60–0.84) 0.58 (0.41–0.74) 0.83 (0.70–0.92)
US (N = 242) 93 65 48 45 132 17 0.52 (0.41–0.62) 0.89 (0.82–0.93) 0.74 (0.62–0.84) 0.75 (0.68–0.81)
HR−/HER2+ MRI (N = 50) 24 21 20 4 25 1 0.83 (0.63–0.95) 0.96 (0.80–1) 0.95 (0.76–1) 0.86 (0.68–0.96)
US (N = 84) 42 22 14 28 34 8 0.33 (0.20–0.50) 0.81 (0.66–0.91) 0.64 (0.41–0.83) 0.55 (0.42–0.68)
Group   ≤10 mm at histology, N ≤10 mm at imaging, N TN, N FP, N TP, N FN, N Specificity (CL) Sensitivity (CL) NPV (CL) PPV (CL)
Overall MRI (N = 224) 151 100 92 59 65 8 0.61 (0.53–0.69) 0.89 (0.80–0.95) 0.92 (0.85–0.96) 0.52 (0.43–0.62)
US (N = 560) 353 306 253 100 154 53 0.72 (0.67–0.76) 0.74 (0.68–0.80) 0.83 (0.78–0.87) 0.61 (0.54–0.67)
HR+/HER2+ MRI (N = 101) 61 30 27 34 37 3 0.44 (0.32–0.58) 0.93 (0.80–0.98) 0.90 (0.74–0.98) 0.52 (0.40–0.64)
US (N = 246) 142 138 106 36 72 32 0.75 (0.67–0.82) 0.69 (0.59–0.78) 0.77 (0.69–0.84) 0.67 (0.57–0.75)
HR−/HER2− MRI (N = 81) 55 45 40 15 21 5 0.73 (0.59–0.84) 0.81 (0.61–0.93) 0.89 (0.76–0.96) 0.58 (0.41–0.74)
US (N = 237) 156 124 107 49 64 17 0.69 (0.61–0.76) 0.79 (0.69–0.87) 0.86 (0.79–0.92) 0.57 (0.47–0.66)
HR−/HER2+ MRI (N = 42) 35 25 25 10 7 0 0.71 (0.54–0.85) 1 (0.59–1) 1 (0.86–1) 0.41 (0.18–0.67)
US (N = 77) 55 44 40 15 18 4 0.73 (0.59–0.84) 0.82 (0.60–0.95) 0.91 (0.78–0.98) 0.55 (0.36–0.72)
  1. TP, true-positive examination; FP, false-positive examination; TN, true-negative examination and FN; false-negative examination. For pCR, TN was defined as CR at imaging and pCR, FP as no CR at imaging and pCR, TP as no CR at imaging and no pCR, and FN as CR at imaging and no pCR. For residual tumor at histology, TN was defined as tumor size of ≤10 mm by imaging and equivalent tumor size at histology, FP was defined as tumor size of > 10 mm by imaging and tumor size of ≤10 mm at histology; TP was defined as tumor size of > 10 mm by imaging and equivalent tumor size at histology, and FN was defined as tumor size of ≤10 mm by imaging and tumor size of > 10 mm at histology. PPV, positive predictive value, defined as P(P = 1|I = 1); NPV, negative predictive value, defined as P(P = 0|I = 0); SENS, sensitivity, defined as P(I = 1|P = 1); SPEC, specificity, defined as P(I = 0|P = 0 where P(A|B) denotes the conditional probability of event A given that event B has occurred. P = 1 denotes a residual invasive tumor size of > 10 mm at histology, and I = 1 denotes tumor size of > 10 mm at imaging; CL, exact 95% confidence limits (Clopper-Pearson)